OLMA - Olema Oncology to Participate at Upcoming Investor Conferences
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company will present at the following upcoming investor conferences:
- Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Citi’s 2023 Virtual Oncology Leadership Summit on Thursday, February 23, 2023, at 12:00 p.m. ET.
- Shane Kovacs, Chief Operating and Financial Officer, will participate in the Breast and Lung Cancer Corporate Panel at Cowen’s 43 rd Annual Healthcare Conference on Tuesday, March 7, 2023, at 10:30 a.m. ET in Boston, MA.
A live webcast of these events will be available under the News & Events section of Olema’s Investor Relations website at www.olema.com and will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
IR Contact :
Courtney Dugan, Vice President, Investor Relations and Communications
ir@olema.com
Media Contact :
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
ignacio.guerrero-ros@russopartnersllc.com